This site is intended for healthcare professionals
Blue, green and purple abstract wave
Drug information

Dermamist

OTC
Read time: 2 mins
Last updated: 02 Dec 2019

Summary of product characteristics


1. Name of the medicinal product

Dermamist


2. Qualitative and quantitative composition

White Soft Paraffin BP 10.0% w/w.


3. Pharmaceutical form

Pressurised aerosol


4.1. Therapeutic indications

Treatment of dry skin conditions including eczema, ichthyosis and pruritus of the elderly.


4.2. Posology and method of administration

Adults, children and the elderly: Shake before use. Bathe or shower for not more than ten minutes. Pat dry and apply spray without delay. Do not spray on face. Spray from a distance of approximately 8 inches. Spray away from the face and move the can while spraying to achieve a very light coverage of the body. Spray sparingly; over application may cause the skin to feel oily.


4.3. Contraindications

Hypersensitivity to any of the ingredients.


4.4. Special warnings and precautions for use

For external use only. Keep out of reach of children. Do not spray on face. Use in a ventilated area. Avoid inhalation. Guard against slipping. Discontinue use if the condition is made worse. Do not apply to broken skin.

Instruct patients not to smoke or go near naked flames – risk of severe burns. Fabric (clothing, bedding, dressings etc) that has been in contact with this product burns more easily and is a serious fire hazard. Washing clothing and bedding may reduce product build-up but not totally remove it.


4.5. Interaction with other medicinal products and other forms of interaction

None.


4.6. Fertility, pregnancy and lactation

Can be used.


4.7. Effects on ability to drive and use machines

Not relevant.


4.8. Undesirable effects

May cause contact dermatitis

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.


4.9. Overdose

None


5.1. Pharmacodynamic properties

Emollients are fats or oils used for their local action on the skin and, occasionally, the mucous membranes. These oleaginous substances, also known as occlusive agents and humectants, are employed as protectives and as agents for softening the skin and rendering it more pliable. White soft paraffin forms an effective occlusive lipid film. The mechanism of action is by occluding water loss from the outer layer of skin.


5.2. Pharmacokinetic properties

White soft paraffin exerts its physiological effects by forming an occlusive layer on the surface of the skin. It is effective because it is not subject to absorption or subsequent distribution in the body, excretion or metabolism. Pharmacokinetic particulars are not appropriate in these circumstances.


5.3. Preclinical safety data

No relevant pre-clinical data has been generated.


6.1. List of excipients

Liquid paraffin BP

Fractionated coconut oil BP

Butane 40 (butane: isobutane: propane) HSE


6.2. Incompatibilities

None


6.3. Shelf life

60 months.


6.4. Special precautions for storage

Store below 25°C. Pressurised container. Highly flammable, Protect from sunlight and do not puncture, burn or expose to temperatures over 50°C even when empty. Do not spray on a naked flame or any incandescent material.


6.5. Nature and contents of container

Pressurised aerosol. Pack sizes 50 ml, 250 ml, 75 ml, 150 ml, 200 ml, 300 ml, 400 ml, and 500 ml.

Not all pack sizes may be marketed.


6.6. Special precautions for disposal and other handling

No special instructions for use or handling.


7. Marketing authorisation holder

Alliance Pharmaceuticals Limited

Avonbridge House

Bath Road

Chippenham

Wiltshire

England

SN15 2BB


8. Marketing authorisation number(s)

PL 16853/0098


9. Date of first authorisation/renewal of the authorisation

15/03/94


10. Date of revision of the text

10th Oct 2019

4.1 Therapeutic indications

Treatment of dry skin conditions including eczema, ichthyosis and pruritus of the elderly.

4.2 Posology and method of administration

Adults, children and the elderly: Shake before use. Bathe or shower for not more than ten minutes. Pat dry and apply spray without delay. Do not spray on face. Spray from a distance of approximately 8 inches. Spray away from the face and move the can while spraying to achieve a very light coverage of the body. Spray sparingly; over application may cause the skin to feel oily.

4.3 Contraindications

Hypersensitivity to any of the ingredients.

4.4 Special warnings and precautions for use

For external use only. Keep out of reach of children. Do not spray on face. Use in a ventilated area. Avoid inhalation. Guard against slipping. Discontinue use if the condition is made worse. Do not apply to broken skin.

Instruct patients not to smoke or go near naked flames – risk of severe burns. Fabric (clothing, bedding, dressings etc) that has been in contact with this product burns more easily and is a serious fire hazard. Washing clothing and bedding may reduce product build-up but not totally remove it.

4.5 Interaction with other medicinal products and other forms of interaction

None.

4.6 Fertility, pregnancy and lactation

Can be used.

4.7 Effects on ability to drive and use machines

Not relevant.

4.8 Undesirable effects

May cause contact dermatitis

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

 

 

Disclaimer

The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC (www.medicines.org.uk/emc/). Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).